Molecular modelling, Synthesis and Antiproliferative Evaluation of New Phenyldiazenyl)-Pyrazol Schiff Base Derivatives

duha emad taha; Monther F. Mahdi; Ayad M. R. Raauf

doi:10.32947/ajps.v24i1.999

Authors

duha emad taha ministry of health
Monther F. Mahdi Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Ayad M. R. Raauf College of Pharmacy, Al-Farahidi University, Baghdad, Iraq

DOI:

https://doi.org/10.32947/ajps.v24i1.999

Keywords:

lung cancer, EGFR receptor, A549, molecular docking, pharmacokinetic study, pyrazole

Abstract

Lung cancer is the most prevalent worldwide. In addition, it is also the most common cause of cancer-related deaths worldwide, with around 1.8 million new cases annually. With a 5-year survival rate of fewer than 20%.

Cytotoxic medicines are commonly employed in cancer treatment. Although the medicine improves patients' quality of life, several disadvantages diminish its efficacy. This necessitates developing new effective strategies that target tumors with minimal adverse effects. This research aims to overcome these issues by synthesizing a new series of phenyldiazenyl)-pyrazol schiff base derivatives by utilizing the molecular docking (GOLD) suite program and the pharmacokinetic properties determination by utilizing (Swiss) ADME suite; The most appropriate-fitting compounds were subsequently produced and confirmed using spectrum analysis (FTIR, ¹HNMR, and ¹³CNMR). MTT in vitro assay were performed to assess of antiproliferative activities against A549 lung cancer cell lines. The antiproliferative study showed that compound 3a had an inhibitory concentration (IC₅₀ of 17.37 µM) on lung cancer cells (A549), which was significantly higher inhibitory activity than Erlotinib (IC₅₀ = 25.06 µM). While compound 3b had an inhibitory activity comparable to the reference drug's, The IC₅₀ values for compounds 3c, 3d, and 3e were 47.48, 45.56, and 33.05 µM, respectively

References

- Saba T. Recent advancement in cancer detection using machine learning: Systematic survey of decades, comparisons and challenges. Journal of Infection and Public Health. 2020 Sep 1;13(9):1274-1289. DOI: https://doi.org/10.1016/j.jiph.2020.06.033

- Mattiuzzi C, Lippi G. Current cancer epidemiology. Journal of epidemiology and global health. 2019 Dec;9(4):217. DOI: https://doi.org/10.2991/jegh.k.191008.001

- Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, Orejana-Martín I, Torres-Jiménez J, Carrato A, Alonso-Gordoa T, Molina-Cerrillo J. Tyrosine kinase receptors in oncology. International journal of molecular sciences. 2020 Nov 12;21(22):8529. DOI: https://doi.org/10.3390/ijms21228529

- Saraon P, Pathmanathan S, Snider J, Lyakisheva A, Wong V, Stagljar I. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene. 2021 Jun 17;40(24):4079-4093. DOI: https://doi.org/10.1038/s41388-021-01841-2

- Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clinical cancer research. 2006 Sep 15;12(18):5268-5272. DOI: https://doi.org/10.1158/1078-0432.CCR-05-1554

- Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019 Nov 14;575(7782):299-309. DOI: https://doi.org/10.1038/s41586-019-1730-1

- Ibrahim NW, Mahdi M, Raauf AM. Design, Molecular Docking, Synthesis and Evaluation of New Isatin Derivatives Bearing Pyridine Moiety as Potential Tyrosine Kinase Inhibitors. Egyptian Journal of Chemistry. 2022 Feb 1;65(2):9-18.

- Alawad KM, Mahdi MF, Raauf AM. Molecular Docking, Synthesis, Characterization and Adme Studies of Some New Five-Member Ring Heterocyclic Compounds with in Vitro Antiproliferative Evaluation. Journal of Hunan University (Natural Science Edition). 2021 Sep;48(9).

- Karrouchi K, Radi S, Ramli Y, Taoufik J, Mabkhot YN, Al-Aizari FA, et al. Synthesis and pharmacological activities of pyrazole derivatives: A review. Molecules. 2018;23(1):134. DOI: https://doi.org/10.3390/molecules23010134

- Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015 Jul 22;20(7):13384-13421. DOI: https://doi.org/10.3390/molecules200713384

- Fadhil HR, Mahdi MF, Raauf AM. MOLECULAR DOCKING, SYNTHESIS, CHARACTERIZATION AND ANTIPROLIFERATIVE EVALUATION OF PYRAZOLINE DERIVATIVES.

- Azab ME, Youssef MM, El-Bordany EA. Synthesis and antibacterial Evaluation of novel heterocyclic compounds containing a sulfonamido moiety. Molecules. 2013;18(1):832–844. DOI: https://doi.org/10.3390/molecules18010832

- Saleh MA, Abdel-Megeed MF, Abdo MA, Shokr A-BM. Synthesis of novel 3H-quinazolin-4-ones containing pyrazolinone, pyrazole and pyrimidinone moieties. Molecules. 2003 ;8(4) :363–373. DOI: https://doi.org/10.3390/80400363

- Elnagdi MH, Sallam MM, Fahmy HM, Ibrahim SA, Elias MA. Reactions with the Arylhydrazones of α‐Cyanoketones: The Structure of 2‐Arylhydrazono‐3‐ketimino‐nitriles. Helvetica Chimica Acta. 1976 Mar 10;59(2):551-7. DOI: https://doi.org/10.1002/hlca.19760590220

- Metwally MA, Gouda MA, Harmal AN, Khalil AM. 3-Iminobutanenitrile as building block for the synthesis of substituted pyrazolo [1, 5-a] pyrimidines with antitumor and antioxidant activities. International Journal of Modern Organic Chemistry. 2012; 1:96-114

- Daina, A., O. Michielin, and V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.Scientific reports, 2017. 7(1): p. 1-13. DOI: https://doi.org/10.1038/srep42717

- Nawaz, F., et al., 3′‐ (4‐ (Benzyloxy) phenyl) ‐1′‐ phenyl‐ 5‐ (heteroaryl/aryl) ‐ 3, 4‐ dihydro‐1′ H, 2H‐ [3, 4′‐ bipyrazole] ‐ 2‐ carboxamides as EGFR kinase inhibitors: Synthesis, anticancer Evaluation, and molecular docking studies. Archivder Pharmazie, 2020. 353(4): p. 1900262. DOI: https://doi.org/10.1002/ardp.201900262

- Park, J.H., et al., Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochemical Journal, 2012. 448(Pt 3): p.417. DOI: https://doi.org/10.1042/BJ20121513

- Yousif OA, Mahdi MF, Raauf AM. Design, synthesis, preliminary pharmacological evaluation, molecular docking and ADME studies of some new pyrazoline, isoxazoline and pyrimidine derivatives bearing nabumetone moiety targeting cyclooxygenase enzyme. Journal of Contemporary Medical Sciences. 2019 Jan;5(1):41-50. DOI: https://doi.org/10.22317/jcms.v5i1.521

- Zhang L, Chen Q, Hou G, Zhao W, Hou Y. Hydroxyl-substituted double Schiff-base condensed 4-piperidone/cyclohexanones as potential anticancer agents with biological Evaluation. Journal of enzyme inhibition and medicinal chemistry. 2019 Jan 1;34(1):264-71. DOI: https://doi.org/10.1080/14756366.2018.1501042

- Adnan, A.M.A., M.F. Mahdi, and A. Kareem Khan, Design, Synthesis, and Acute Anti-inflammatory Assessment of New 2-methyl Benzoimidazole Derivatives Having 4- Thiazolidinone Nucleus. Al-Mustansiriyah Journal of Pharmaceutical Sciences (AJPS), 2019. 19(4): p. 151-160. DOI: https://doi.org/10.32947/ajps.v19i4.646

- Wabdan AK, Mahdi MF, Khan AK. Molecular Docking, Synthesis and ADME Studies of New Pyrazoline Derivatives as Potential Anticancer Agents. Egyptian Journal of Chemistry. 2021 Aug 1;64(8):4311-4322.

- Sahoo RN, Pattanaik S, Pattnaik G, Mallick S, Mohapatra R. Review on the use of Molecular Docking as the First Line Tool in Drug Discovery and Development. Indian Journal of Pharmaceutical Sciences. 2022 Oct 31;84(5):1334-1337. DOI: https://doi.org/10.36468/pharmaceutical-sciences.1031

- Shaikh N, Linthoi RK, Swamy KV, Karthikeyan M, Vyas R. Comprehensive molecular docking and dynamic simulations for drug repurposing of clinical drugs against multiple cancer kinase targets. Journal of Biomolecular Structure and Dynamics. 2022 Sep 14:1-9. DOI: https://doi.org/10.1080/07391102.2022.2124453